Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,050 recruiting studies in this area right now.
By phase
- Not applicable2,999
- Phase 21,056
- Phase 1792
- Phase 1/Phase 2437
- Phase 3435
- Phase 4233
- Phase 2/Phase 398
Top conditions
- Multiple Sclerosis330
- Multiple Myeloma327
- Asthma193
- Lymphoma178
- Rheumatoid Arthritis131
- Type 1 Diabetes130
- Atopic Dermatitis124
- Systemic Lupus Erythematosus119
- Acute Lymphoblastic Leukemia118
- HIV Infections106
- Chronic Lymphocytic Leukemia95
- Autoimmune Diseases77
- Follicular Lymphoma70
- Rheumatoid Arthritis (RA)68
- Diabetes Mellitus, Type 163
- Hodgkin Lymphoma63
- Leukemia63
- Mantle Cell Lymphoma62
Leading sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)97
- Institute of Hematology & Blood Diseases Hospital, China85
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris65
- AstraZeneca63
- M.D. Anderson Cancer Center58
- Novartis Pharmaceuticals58
- Mayo Clinic49
- City of Hope Medical Center48
- Memorial Sloan Kettering Cancer Center45
Where studies are running
- California496
- Maryland199
- Alabama178
- Florida149
- Arizona148
- Massachusetts116
- New York116
- Texas112
- Illinois83
- Colorado82
Recruiting studies6,050 total
- NCT06754267RecruitingPhase 2
Studying a new drug combo for Ph+ B-ALL
This trial tests a combination of three drugs (venetoclax, olverembatinib, and prednisone) for adults newly diagnosed with Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia (Ph+ B-ALL). The goal is to see if this combination is safe and effective.
Hangzhou, ZhejiangAges 18 years+ - NCT06654596Recruiting
Telitacicept for IgA nephropathy
This study tests a new medicine called telitacicept for people with IgA nephropathy, a kidney disease that causes protein in the urine. The goal is to see if it safely reduces kidney damage.
ShanghaiAges 18–70 - NCT06734871RecruitingPhase 1
Study of CT1190B for relapsed or refractory B-cell lymphoma
This trial tests an experimental drug called CT1190B for people with a type of blood cancer (B-cell non-Hodgkin lymphoma) that has come back or stopped responding to at least two prior treatments. The study aims to see if the drug can help control the disease.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06755775Recruiting
PET scan to predict immunotherapy success in DLBCL
This trial uses a special PET scan to see if a protein called Granzyme B can predict how well immunotherapy will work for people with DLBCL. It aims to help doctors know earlier if treatment is effective.
ShanghaiAges 18 years+ - NCT07516379Recruiting
Understanding Lung Rejection After Transplant
This study follows people with serious lung disease before and after lung transplant to understand how rejection happens and what warning signs to watch for. By studying your blood, tissue samples, and imaging, researchers hope to better predict and prevent transplant rejection.
Bethesda, MarylandAges 18–75 - NCT07523542RecruitingPhase 1/Phase 2
CAR-T Cell Therapy for Treatment-Resistant Lupus
This study tests a new type of immune cell therapy (CAR-T cells) designed to target and reduce the immune cells driving lupus in patients whose disease hasn't responded to standard treatments. Researchers will first identify which specific immune cells are causing your lupus, then engineer your own immune cells to fight them.
Shenzhen, GuangdongAges 18–70 - NCT07522099RecruitingPhase 2
Study of ADARx Treatment for Kidney Disease in Chinese Adults
This study tests a new ADARx medicine in Chinese adults with specific types of kidney disease (IgAN, C3G, or IC-MPGN). The goal is to see if this treatment can slow kidney damage and help preserve kidney function.
Shenzhen, GuangdongAges 18 years+ - NCT07517250Recruiting
Study of Canakinumab for Fever and Joint Disease
This is a study looking back at patients who were already treated with a medicine called canakinumab for familial Mediterranean fever or Still's disease (rare conditions that cause fevers and joint pain). Researchers want to understand how well this medicine worked over time and what happened to patients who took it.
BaselAges 1 year+ - NCT07518186RecruitingPhase 3
Comparing Two New Myeloma Treatments: JNJ-79635322 vs Teclistamab
This study compares two new antibody-based drugs (JNJ-79635322 and teclistamab) to see which works better for multiple myeloma that has come back or stopped responding to prior treatment. Both drugs are designed to help your immune system fight myeloma cells.
Birmingham, AlabamaAges 18 years+ - NCT07517575RecruitingPhase 2
Olokizumab for Children with Juvenile Idiopathic Arthritis
This trial tests a new medicine called olokizumab in children and teenagers with juvenile idiopathic arthritis (JIA)—a condition where the immune system causes joint inflammation and pain. The study checks if this drug is safe and effective for children whose arthritis hasn't improved enough with standard treatments.
Kazan'Ages 2–17 - NCT07520006RecruitingPhase 1/Phase 2
NX-5948 With Other Drugs for B-cell Blood Cancers
This early-stage study tests a new drug called NX-5948, given alongside other cancer treatments, for adults with B-cell lymphomas and leukemias (including chronic lymphocytic leukemia, or CLL). The goal is to see if this combination helps control the disease, especially in patients whose cancer has come back or stopped responding to prior treatments.
Aurora, ColoradoAges 18 years+ - NCT07523555RecruitingPhase 1/Phase 2
Dual-Target CAR-T Cells for Blood Cancers That Haven't Responded to Treatment
This study tests a new type of cell therapy called CAR-T cells that are designed to target two different proteins on cancer cells. These cells are made from your own immune cells, trained in the lab, and then put back into your body to fight blood cancers that have come back or stopped responding to previous treatments.
Shenzhen, GuangdongAges 18–75 - NCT07519902RecruitingPhase 3
Cenegermin Eye Drops for Persistent Corneal Ulcers
This study tests whether cenegermin eye drops help heal stubborn corneal ulcers (open sores on the clear front of the eye) that haven't improved with standard treatments like lubricating drops or contact lenses.
Huntington Beach, CaliforniaAges 18 years+ - NCT04218318Recruiting
Stopping light therapy early in newborns with blood breakdown
This study looks for a safe threshold to stop the “light therapy” (phototherapy) in newborns who have jaundice caused by blood cell breakdown (hemolytic disease). It may help some babies avoid unnecessary extra days of treatment while still staying safe.
MadinahAges 1 hour–2 weeks - NCT06755619Recruiting
ctDNA testing for response in first-line PCNSL treatment
This study tests whether a blood test (ctDNA) can help doctors see how well treatment is working for people with a type of brain lymphoma (PCNSL) who are getting their first treatment with a cure in mind.
HelsinkiAges 18–70 - NCT07517510Enrolling by invitationPhase 2
HVA treatment for newly diagnosed mixed-phenotype acute leukemia
This study tests a drug called HVA to treat mixed-phenotype acute leukemia (MPAL), a rare blood cancer that has features of both lymphoblastic and myeloid leukemias. You may qualify if you've just been diagnosed and haven't started strong anti-cancer treatment yet.
Guangzhou, GuangdongAges 18 years+ - NCT07524231Recruiting
Laughter Yoga Effects on Health and Well-being
This study tests whether laughter yoga—guided exercises that combine laughter with breathing—can improve health outcomes. Researchers will measure how it affects participants' physical and mental well-being over time.
ElâzığAges 18 years+ - NCT07517536Enrolling by invitation
CHT105 treatment for hard-to-treat lupus kidney disease
This study tests a new medicine called CHT105 for lupus patients whose kidney disease hasn't improved with standard treatments. The medicine targets specific immune cells that may be driving the kidney damage.
Nanjing, JiangsuAges 18–65 - NCT07524543Recruiting
Severe asthma registry study in Hong Kong
This study collects health information from adults with severe asthma to better understand the condition and improve treatment. Your participation involves sharing medical data to help researchers learn more about what works best for severe asthma.
Hong KongAges 18–120 - NCT07522008Recruiting
Testing a blood-cleaning add-on for dialysis symptom relief
This trial tests whether adding a special blood-filtering device (hemoadsorption) to your regular dialysis treatment can reduce uncomfortable symptoms caused by kidney failure, like fatigue or itching. Researchers will track how you feel over time compared to standard dialysis alone.
Cagliari, ItalyAges 18 years+ - NCT07519356Recruiting
Registry for blood and lymph node disorders
This study collects information from patients with lymphoproliferative disorders—conditions affecting blood and lymph cells—to help doctors better understand these diseases and improve care. Your medical records and information may be used to support research that could benefit future patients.
Pavia, LombardyAges 18 years+ - NCT07516548Recruiting
Long-acting HIV prevention and birth control study
This research studies how two types of long-acting birth control (a shot called cabotegravir and an implant) work in your body after pregnancy, and how they interact with HIV prevention or treatment. The study helps doctors understand the best doses and timing for women like you.
Bontleng, GaboroneAges 18 years+ - NCT07524244Recruiting
Ketogenic and carnivore diets for IBD and rheumatoid arthritis
This study tests whether special diets (ketogenic or carnivore/meat-based) can help reduce inflammation and symptoms in people with inflammatory bowel disease or rheumatoid arthritis. You'll follow dietary guidelines for 3 weeks, then continue in the study while researchers track how you respond.
Charlottesville, VirginiaAges 18–64 - NCT07517185RecruitingPhase 2
Early aggressive treatment for relapsing multiple sclerosis
This trial tests whether treating relapsing multiple sclerosis (RRMS) aggressively and early with a specific medication can slow disease progression. You may qualify if you were recently diagnosed, have had recent disease activity, and are willing to take a strong immunosuppressive drug with regular MRI monitoring.
FalunAges 18–50
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,050 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,115 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.